Holen Sie sich die Stockscreener-App
15.42
6.64%
0.96
Handel nachbörslich:
15.42
Schlusskurs vom Vortag:
$14.46
Offen:
$14.52
24-Stunden-Volumen:
289.69K
Relative Volume:
0.87
Marktkapitalisierung:
$1.97B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+23.66%
1M Leistung:
+12.15%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$14.41
$15.47
1-Wochen-Bereich:
$12.03
$15.47
52-Wochen-Spanne:
$11.00
$15.47
Generate Biomedicines Inc Stock (GENB) Company Profile
Firmenname
Generate Biomedicines Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare GENB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GENB
Generate Biomedicines Inc
|
15.42 | 1.84B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Generate Biomedicines Inc Stock (GENB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-03-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-03-24 | Eingeleitet | Goldman | Buy |
| 2026-03-24 | Eingeleitet | Guggenheim | Buy |
| 2026-03-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2026-03-24 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Generate Biomedicines Inc Aktie (GENB) Neueste Nachrichten
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
GENB Generate Biomedicines leadership flags accelerated AI drug pipeline advancement as top priority in latest quarterly earnings update.Revenue Guidance - Newser
Generate Biomedicines (GENB) Stock Public Float (Smart Money Outflows) 2026-04-27IPO Watch - Newser
GENB Price History for Generate Biomedicines Stock - Barchart.com
Generate Biomedicines Inc (GENB) Stock Price, Quote, News & History - Benzinga
Generate Biomedicines (GENB) Stock Price, News & Analysis - MarketBeat
H.C. Wainwright Initiates Coverage of Generate Biomedicines (GENB) With a Buy Rating - insidermonkey.com
Generate Biomedicines (GENB) Stock: Investment Analysis (Grinds Lower) 2026-04-18High Attention Stocks - Newser
GENB Stock Price, News & Analysis - Stock Titan
Preferred dividends of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
GENB Forecast — Price Target — Prediction for 2027 - TradingView
Generate Biomedicines, Inc. News — NASDAQ:GENB - TradingView
Long term debt to total equity ratio of Generate Biomedicines, Inc. – BX:GENB - TradingView — Track All Markets
Preferred dividends of Generate Biomedicines, Inc. – BX:GENB - TradingView — Track All Markets
This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Sahm
GENB Price Today: Generate Biomedicines, Inc. Stock Price, Quote & Chart | MEXC - MEXC
GENB Initiated Coverage by HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
HC Wainwright Initiates Generate Biomedicines at Buy With $16 Price Target - marketscreener.com
IPO Tracker 2026: Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinic - BioSpace
Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - GlobeNewswire Inc.
Will Generate Biomedicines (GENB) Stock Hit Record Highs | Price at $12.10, Down 12.00%Market Expert Watchlist - UBND thành phố Hải Phòng
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
Cantor Fitzgerald reiterates Generate Biomedicines stock rating By Investing.com - Investing.com Canada
GENB | Generate Biomedicines, Inc. Common Analyst Forecasts - Quiver Quantitative
IPO Tracker 2026: Biotech Mega-Rounder Kailera Seeks IPO - BioSpace
Kailera Therapeutics files for US IPO - MarketScreener
Flagship-backed Generate Bio seeks $425 million in US IPO - MSN
Generate Biomedicines (NASDAQ:GENB) Rating Increased to Hold at Zacks Research - MarketBeat
Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - FinancialContent
This KB Home Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Sahm
Generate Biomedicines gains buy initiations from Guggenheim, Piper Sandler - MSN
The Goldman Sachs Group Initiates Coverage on Generate Biomedicines (NASDAQ:GENB) - MarketBeat
Morgan Stanley Initiates Coverage on Generate Biomedicines (NASDAQ:GENB) - marketbeat.com
Generate Biomedicines (NASDAQ:GENB) Coverage Initiated at Guggenheim - marketbeat.com
Generate Biomedicines (NASDAQ:GENB) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat
Goldman Sachs Initiates Coverage on Generate Biomedicines With Buy Rating, $26 Price Target - marketscreener.com
Guggenheim Initiates Coverage on Generate Biomedicines With Buy Rating, $30 Price Target - marketscreener.com
Piper Sandler initiates Generate Biomedicines stock at overweight By Investing.com - Investing.com Canada
Morgan Stanley Initiates Generate Biomedicines at Overweight With $20 Price Target - marketscreener.com
Morgan Stanley initiates Generate Biomedicines stock at overweight By Investing.com - Investing.com Canada
Piper Sandler initiates Generate Biomedicines stock at overweight - Investing.com
Morgan Stanley initiates Generate Biomedicines stock at overweight - Investing.com
Goldman Sachs initiates Generate Biomedicines stock with buy rating on AI platform potential - Investing.com
Guggenheim initiates Generate Biomedicines stock with buy rating By Investing.com - Investing.com Australia
Guggenheim initiates Generate Biomedicines stock with buy rating - investing.com
ETFs Investing in Generate Biomedicines, Inc. Stocks - TradingView — Track All Markets
Generate Biomedicines IPO Turns Heads - Yahoo! Finance Canada
Generate Biomedicines (GENB) Stock Trends and Sentiment 2026 - MarketBeat
Finanzdaten der Generate Biomedicines Inc-Aktie (GENB)
Es liegen keine Finanzdaten für Generate Biomedicines Inc (GENB) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):